Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy

Cephalalgia

Volumn 17, Issue 18_suppl, 1997, Pages 28-40

  Schoenen, J ^a   Sawyer, J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ASTRAZENECA   (United Kingdom)

Author keywords

5HT1B 1D receptor agonists; Clinical trials; migraine; zolmitriptan

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN; ORAL CONTRACEPTIVE AGENT; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; AROUSAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG USE; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; MIGRAINE; NAUSEA; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PHONOPHOBIA; PHOTOPHOBIA; PREMEDICATION; PROCESS DEVELOPMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; SCHOOL CHILD; TREATMENT OUTCOME; CHILD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MENSTRUATION; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; OXAZOLES; OXAZOLIDINONES; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 34547943913     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102497017S1805     Document Type: Review

References (27)

1. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996; 36 Suppl 2: 13-18
2. Dechant KL, Clissold SP., Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 776-98
3. Dixon R, Warrander A., The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl 18: 15-20
4. 1B/1D agonist for migraine. Cephalalgia 1997; 17 Suppl 18: 4-14
5. 1B/1D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355-9
6. 1D agonists used in acute migraine treatment. Cephalalgia 1997; 17: 388 (Abs 06-A 09)
7. 1B/1D agonist. Cephalalgia 1997; 17 Suppl 18: 41-52
8. ×). Cephalalgia 1997; 17 Suppl 18: 21-7
9. Schoenen J, Caekebeke P, Louis G, Monseu G, Phillips S, Pierre P., An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of an efficacy in migraine patients. In: Rose FC, editor. Proceedings of the 10th Migraine Trust Symposium, New Advances in Headache Research 4. London: Smith-Gordon, 1994: 11-12
10. Pilgrim AJ., Lessons learned from the clinical development of sumatriptan. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment; trial methodology and new drugs. Philadelphia: Lippincott-Raven Publishers, 1997: 119-24
11. 1D receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46: 552-6
12. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al. A multicenter, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995; 35: 292 (Abs 19)
13. th International Headache Congress, Toronto, 16-20 Sept 1995
14. Lowy MT, for the US 311C 2.5 mg Study Group. 2.5 mg 311C90 in the acute treatment of migraine: efficacy and safety. Eur J Neurol 1996; 3 Suppl 5: 152 (Abs P409)
15. rd European Headache Conference, Sardinia, June 5-8 1996: 10-11. Extended abstracts of an official symposium: 311C90: Potential for improving patient care, 6 June 1996
16. 1B/1D agonists. Neurology 1997; 48 Suppl. 3: S21-4
17. Zagami AS, for the International 311C90 Long-term Study Group. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 1997; 48 Suppl 3: S25-8
18. Solomon GD., Evolution of the measurement of quality of life in migraine. Neurology 1997; 48: S10-15
19. McKenna S, Patrick D., Development of a migraine specific quality of life measure for multinational clinical trials. Cephalalgia 1995; 15 Suppl 14: 280
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 1-96
21. Rapoport AM, Ward T, Katz DA, Sheftell FD., Zolmitriptam ("Zomig"): rapid onset of migraine relief. Cephalalgia 1997; 17: 422
22. nd Congress of the European Federation of Neurological Sciences, Rome, 30 Oct-3 Nov 1996
23. th World Congress on Pain, Vancouver Aug 17-22, 1996: 499-500 (Abs)
24. Bousser MG, D'Allens H, Richard A., Efficacy of subcutaneous sumatriptan in the acute treatment of early morning migraine. J Intern Med 1993; 234: 211-16
25. Goadsby PJ., Diagnosis and optimum treatment of migraine. CNS Drugs 1994; 1: 245-53
26. Dahlöf CGH, Dimenas F., Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31-6
27. Osterhaus JT, Townsend RJ, Gandek B, Ware JK., Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337-43